title: Ezetimibe therapy and its influence on oxidative stress and fibrinolytic activity.
abstract: OBJECTIVE
  The effect of ezetimibe on blood lipids, oxidative stress, and fibrinolytic activity in hyperlipidemic patients was investigated after three months of therapy.
  
  
  METHODS
  Thirty hyperlipidemic patients were treated for twelve weeks with ezetimibe 10 mg/day. A healthy control group with matching age and gender was also included. Fasting blood glucose, lipid parameters, paraoxonase (PON1), protein carbonyl (PCO), oxidized LDL (oxLDL), 8-isoprostane (ISOPR), total antioxidant capacity (TAC) levels, tissue-type plasminogen activator (tPA), plasminogen activator inhibitor type-1 (PAI-1), and PAI-1/t-PA levels were evaluated.
  
  
  RESULTS
  Ezetimibe therapy for twelve weeks led to changes in lipid profile in accordance with the literature. Fibrinolytic activity parameters, PAI-1/tPA and tPA-1 decreased, whereas PAI-1 levels did not change significantly. Antioxidant parameters, serum PON1 activity, and TAC levels increased significantly compared with the basal values. Oxidant parameters, oxLDL, ISOPR, and PCO (which is an indicator of oxidative protein damage) decreased significantly after therapy.
  
  
  CONCLUSIONS
  Ezetimibe therapy has beneficial effects on fibrinolytic activity and homeostasis between oxidant and antioxidant activity in hyperlipidemic patients This may be through lowering lipid levels or other mechanisms such as decreasing insulin resistance and the pleiotropic effects of the drug.
authors.affiliation: Cerrahpasa Medical Faculty, University of Istanbul, Turkey. nurverdi@gmail.com
authors.forename: Nurver
authors.initials: N
authors.lastname: Turfaner
authors.forename: Hafize
authors.initials: H
authors.lastname: Uzun
authors.forename: Huriye
authors.initials: H
authors.lastname: Balci
authors.forename: Meltem A
authors.initials: MA
authors.lastname: Ercan
authors.forename: Yesari H
authors.initials: YH
authors.lastname: Karter
authors.forename: Metin
authors.initials: M
authors.lastname: Caner
authors.forename: Fikret
authors.initials: F
authors.lastname: Sipahioglu
authors.forename: Habibe
authors.initials: H
authors.lastname: Genc
mesh_terms: D000328:Adult; D000924:Anticholesteremic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D000975:Antioxidants / Q000378:metabolism; D043303:Aryldialkylphosphatase / Q000097:blood; D001384:Azetidines / Q000494:pharmacology / Q000627:therapeutic use*; D001786:Blood Glucose / Q000032:analysis; D000069438:Ezetimibe; D005260:Female; D005342:Fibrinolysis / Q000187:drug effects*; D006801:Humans; D006949:Hyperlipidemias / Q000097:blood / Q000188:drug therapy; D028421:Isoprostanes / Q000097:blood; D008055:Lipids / Q000097:blood; D008077:Lipoproteins, LDL / Q000097:blood; D008297:Male; D008875:Middle Aged; D018384:Oxidative Stress / Q000187:drug effects*; D017395:Plasminogen Activator Inhibitor 1 / Q000097:blood; D050050:Protein Carbonylation / Q000187:drug effects; D010959:Tissue Plasminogen Activator
chemical_list: D000924:Anticholesteremic Agents; D000975:Antioxidants; D001384:Azetidines; D001786:Blood Glucose; D028421:Isoprostanes; D008055:Lipids; D008077:Lipoproteins, LDL; D017395:Plasminogen Activator Inhibitor 1; C099252:oxidized low density lipoprotein; D043303:Aryldialkylphosphatase; D010959:Tissue Plasminogen Activator; D000069438:Ezetimibe